Polypod-like structured guanine-rich oligonucleotide aptamer as a selective and cytotoxic nanostructured DNA to cancer cells.


Journal

Journal of drug targeting
ISSN: 1029-2330
Titre abrégé: J Drug Target
Pays: England
ID NLM: 9312476

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 1 10 2020
medline: 15 12 2021
entrez: 30 9 2020
Statut: ppublish

Résumé

Guanine-rich oligonucleotide (GRO) can be developed as an effective anticancer agent owing to its high selectivity, affinity and antiproliferative activity in cancer cells. In this study, to increase the potency of GRO29A, a 29-mer GRO aptamer against nucleolin, an overexpressed protein in cancer cells, GRO29A was incorporated into three or six pods of polypod-like structured DNA (polypodna), tripodna or hexapodna, respectively. The polypod-like structured GROs, tri-G3, consisting of one tripodna and three GRO29A, or hexa-G1, hexa-G3 or hexa-G6, each of which comprises one hexapodna and one, three or six GRO29A, respectively, were designed. Tri-G3, hexa-G1 and hexa-G3 were prepared in high yield, except for hexa-G6. Polypod-like structured GROs had quadruplex structures under physiological salt conditions, and degraded at a slower rate in buffer containing serum. Cellular interaction experiments using fluorescently labelled DNA samples showed that the uptake of hexa-G3 by nucleolin-positive MCF-7 cells was more than 2-fold higher than GRO29A, and the interaction was increasingly dependent on the number of GRO29A in the structures. Hexa-G3 inhibited the proliferation of MCF-7 cells in more than 40%, but not of CHO cells. These results indicate that polypod-like structured GROs are useful DNA aptamers with high selectivity and cytotoxicity against nucleolin-positive cancer cells.

Identifiants

pubmed: 32997541
doi: 10.1080/1061186X.2020.1830407
doi:

Substances chimiques

Aptamers, Nucleotide 0
Phosphoproteins 0
RNA-Binding Proteins 0
Guanine 5Z93L87A1R
DNA 9007-49-2

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-224

Auteurs

Kohta Mohri (K)

Faculty of Pharmaceutical Sciences, Laboratory of Drug Delivery System, Setsunan University, Hirakata, Japan.
Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.

Emi Hayashi (E)

Faculty of Pharmaceutical Sciences, Laboratory of Drug Delivery System, Setsunan University, Hirakata, Japan.

Manato Nishino (M)

Faculty of Pharmaceutical Sciences, Laboratory of Drug Delivery System, Setsunan University, Hirakata, Japan.

Nao Matsushita (N)

Faculty of Pharmaceutical Sciences, Laboratory of Drug Delivery System, Setsunan University, Hirakata, Japan.

Sohei Tanishita (S)

Faculty of Pharmaceutical Sciences, Laboratory of Drug Delivery System, Setsunan University, Hirakata, Japan.

Makiya Nishikawa (M)

Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Faculty of Pharmaceutical Sciences, Laboratory of Biopharmaceutics, Tokyo University of Science, Noda, Japan.

Shinji Sakuma (S)

Faculty of Pharmaceutical Sciences, Laboratory of Drug Delivery System, Setsunan University, Hirakata, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH